text
"['\nIX. 계열회사 등에 관한 사항\n1. 계열회사에 관한 사항\n2019년 09월\xa030일\xa0기준일 현재\xa0당사를 포함하여 종근당그룹 계열현황은 다음과 같습니다.\xa0 \xa0\xa0가. 기업집단의 명칭 종근당그룹나.\xa0계열회사간의 업무조정이나 이해관계를 조정하는 기구 또는 조직해당사항없음다.\xa0계열회사 중\xa0당해 회사의 경영에 직접 또는 간접으로 영향력을 미치는 회사해당사항없음라. 공정거래법에 따른 상호출자제한, 출자총액제한, 채무보증 제한 대상 여부해당사항이 없음마.\xa0계열회사간 상호 지분관계\xa0\n(2019년 3분기말 현재)\n회\xa0 사\xa0 명(사업자등록번호)\n투자지분 현황\n비\xa0 고\n1\n\xa0(주)종근당홀딩스(113-81-06667)\n\xa0종근당산업(주) 57.55%, (주)벨이앤씨 42.38% (주)벨커뮤니케이션즈 51.00%, 종근당건강(주) 51.00%, (주)경보제약 43.41%, (주)종근당바이오 37.21%, (주)종근당 23.23%, (주)벨아이앤에스 40.00%\n상장\n2\n\xa0(주)종근당(110-86-08069)\n\xa0PT CKD OTTO PHARMACEUTICALS 70.00%\n상장\n3\n\xa0(주)종근당바이오(110-81-53652)\n\xa0CKDBio Australia Pty Ltd 100%\n상장\n4\n\xa0(주)경보제약(312-81-04567)\n\xa0Bardia Farma 100%\n상장\n5\n\xa0종근당산업(주)(110-81-07992)\n\xa0-\n비상장\n6\n\xa0(주)벨이앤씨(124-81-47431)\n\xa0-\n비상장\n7\n\xa0(주)벨커뮤니케이션즈(110-81-33831)\n-\n비상장\n8\n\xa0종근당건강(주)(134-81-29992)\n\xa0(주)텔라이프 50.00%, (주)그린웨이코리아 55.00% (주)에이뉴힐 100.00%, QingDao Zhong Gen Tang Health Co.,Ltd 100.00%\n비상장\n9\n\xa0CKD창업투자(주)(306-81-29961)\n-\n비상장\n10\n\xa0(주)벨에스엠(107-86-80124)\n-\n비상장\n11\n\xa0(주)벨아이앤에스(110-81-82195)\n-\n비상장\n12\n(주)텔라이프(741-88-00832)\n-\n비상장\n13\n(주)그린웨이코리아(125-88-01136)\n-\n비상장\n14\n(주)에이뉴힐(773-87-01224)\n-\n비상장\n15\n\xa0Bardia Farma SPA\n-\n해외법인\n16\nPT CKD OTTO PHARMACEUTICALS\n-\n해외법인\n17\nQingDao Zhong Gen Tang Health Co.,Ltd\n-\n해외법인\n18\nCKDBio Australia Pty Ltd\xa0\n-\n해외법인\n2. 타법인출자 현황\n(기준일 :\xa0\n2019년 09월 30일\n)\n(단위 : 원, 백만주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n경보제약 (상장)\n1996.01.01\n경영참가\n23,603\n10,377,045\n43.4\n44,185\n\xa0-\n\xa0-\n\xa0-\n10,377,045\n43.4\n44,185\n221,623\n13,116\n종근당건강 (비상장)\n1996.01.01\n경영참가\n229\n5,227,500\n51.0\n2,571\n\xa0-\n\xa0-\n\xa0-\n5,227,500\n51.0\n2,571\n90,899\n20,896\n벨이앤씨 (비상장)\n1998.01.01\n경영참가\n1,688\n186,853\n42.4\n652\n\xa0-\n\xa0-\n\xa0-\n186,853\n42.4\n652\n9,004\n80\n벨커뮤니케이션즈 (비상장)\n1994.01.01\n경영참가\n750\n145,000\n90.6\n750\n-63,400\n-328\n\xa0-\n81,600\n51.0\n422\n13,714\n1,304\n종근당산업 (비상장)\n1994.01.01\n경영참가\n5,394\n504,152\n57.6\n26,583\n\xa0-\n\xa0-\n\xa0-\n504,152\n57.6\n26,583\n28,907\n970\n종근당바이오 (상장)\n2001.11.12\n경영참가\n2,045\n1,946,007\n37.2\n61,025\n\xa0-\n\xa0-\n\xa0-\n1,946,007\n37.2\n61,025\n184,520\n7,956\n종근당 (상장)\n2013.11.05\n경영참가\n51,908\n2,169,293\n22.0\n160,623\n239,240\n12,819\n\xa0-\n2,408,533\n23.1\n173,442\n698,149\n42,569\nCKD5호코리아더블 타임벤처투자조합\n2013.01.08\n경영참가\n1,600\n16\n53.3\n1,231\n\xa0-\n\xa0-\n\xa0-\n16\n53.3\n1,231\n2,409\n612\nCKDStart-Up1호\xa0 벤처투자조합\n2014.09.02\n경영참가\n200\n5\n3.5\n366\n\xa0-\n\xa0-\n\xa0-\n5\n3.5\n366\n10,870\n2,098\nCKD 바이오헬스케어 Corporate Fund 1호\n2017.12.12\n경영참가\n4,520\n791\n75.3\n7,693\n339\n3,390\n\xa0-\n1,130\n75.3\n11,083\n10,287\n-280\nCKD-BS 스타트업조합펀드 1호\n2018.11.08\n경영참가\n650\n65\n6.7\n660\n\xa0-\n\xa0-\n\xa0-\n65\n6.7\n660\n10,008\n-101\n벨아이앤에스 (비상장)\n2015.11.12\n경영참가\n3,899\n160,000\n40.0\n2,969\n\xa0-\n\xa0-\n\xa0-\n160,000\n40.0\n2,969\n7,274\n143\n한미약품\n2015.11.13\n단순투자\n720\n1,112\n0.0\n516\n22\n\xa0-\n-203\n1,134\n0.0\n313\n1,393,832\n12,762\n대한약품\n2016.01.26\n단순투자\n2,837\n113,802\n1.9\n4,364\n\xa0-\n\xa0-\n-791\n113,802\n1.9\n3,573\n234,755\n28,518\n삼일제약\n2016.01.26\n단순투자\n822\n70,635\n1.3\n1,455\n\xa0-\n\xa0-\n155\n70,635\n1.1\n1,610\n147,592\n-8,552\n헬릭스미스\n2018.03.21\n단순투자\n742\n17,267\n0.1\n4,386\n-854\n-1,069\n-2,229\n16,413\n0.1\n1,088\n269,313\n-28,683\n메지온\n2018.03.21\n단순투자\n418\n28,962\n0.3\n2,665\n-5,245\n-105\n362\n23,717\n0.3\n2,922\n69,570\n-16,724\nSK하이닉스\n2018.03.22\n단순투자\n297\n4,192\n0.0\n254\n160\n-0\n104\n4,352\n\xa0-\n358\n60,980,607\n15,407,085\n차바이오텍\n2018.03.26\n단순투자\n177\n11,407\n0.0\n230\n\xa0-\n\xa0-\n-76\n11,407\n0.0\n155\n283,637\n-13,311\n케이엠더블유\n2018.03.27\n단순투자\n26\n1,204\n0.0\n27\n466\n10\n85\n1,670\n0.0\n122\n278,865\n-31,793\nLG화학\n2018.09.21\n단순투자\n55\n161\n\xa0-\n56\n199\n64\n-12\n360\n\xa0-\n108\n23,730,578\n1,581,064\n아이디스\n2018.10.05\n단순투자\n343\n16,602\n0.0\n351\n99,614\n2,213\n1,062\n116,216\n1.1\n3,626\n165,365\n4,826\n삼성SDI\n2018.12.18\n단순투자\n21\n105\n\xa0-\n23\n696\n159\n-4\n801\n\xa0-\n179\n15,306,118\n525,837\nSBI핀테크솔루션즈\n2019.02.19\n단순투자\n184\n\xa0-\n\xa0-\n\xa0-\n14,456\n184\n-28\n14,456\n0.1\n157\n306,383\n9,446\n이노메트리\n2019.04.01\n단순투자\n1,029\n\xa0-\n\xa0-\n\xa0-\n32,741\n1,029\n-30\n32,741\n0.7\n999\n60,036\n5,434\n바이오오케스트라\n2019.08.09\n단순투자\n4,999\n\xa0-\n\xa0-\n\xa0-\n8,374\n4,999\n\xa0-\n8,374\n5.0\n4,999\n3,871\n-684\n지플러스생명과학\n2019.08.08\n단순투자\n1,000\n\xa0-\n\xa0-\n\xa0-\n50,000\n1,000\n\xa0-\n50,000\n0.5\n1,000\n13,190\n-3,830\n합 계\n-\n-\n323,636\n-\n18,367\n-1,603\n-\n-\n340,399\n-\n-\n주) 분기말 현재 해당 법인에 대한 출자비율이 5% 미만이거나, 장부가액이 1억원 미만인 경우 기재 생략\n']"
